Regulatory FDA hands another rejection to Replimune’s melanoma therapy PharmaphorumReplimune has had its advanced melanoma treatment RP1 turned down by the FDA for a second time, prompting job losses.RegulatoryOncologyRead full story pharminent April 13, 2026 (Last updated: April 13, 2026) Pharmaphorum Replimune has had its advanced melanoma treatment RP1 turned down by the FDA for a second time, prompting job losses. RegulatoryOncologyRead full story Post navigation Previous: Bayer wins MHRA approval for Kerendia in heart failureNext: FDA issues complete response letter to Replimune’s RP1 for melanoma Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026